Early Initiation of Antitumor Necrosis Factor Therapy Reduces Postoperative Recurrence of Crohn's Disease Following Ileocecal Resection

被引:17
作者
Axelrad, Jordan E. [1 ]
Li, Terry [2 ]
Bachour, Salam P. [3 ]
Nakamura, Takahiro, I [4 ]
Shah, Ravi [3 ]
Sachs, Michael C. [5 ]
Chang, Shannon [1 ]
Hudesman, David P. [1 ]
Holubar, Stefan D. [6 ]
Lightner, Amy L. [6 ]
Barnes, Edward L. [7 ]
Cohen, Benjamin L. [8 ]
Rieder, Florian [8 ]
Esen, Eren [9 ]
Remzi, Feza [9 ]
Regueiro, Miguel [8 ]
Click, Benjamin [8 ]
机构
[1] NYU, Dept Med, Divison Gastroenterol, Grossman Sch Med, New York, NY 10016 USA
[2] NYU, Dept Med, Grossman Sch Med, New York, NY 10016 USA
[3] Case Western Reserve Univ, Lerner Coll Med, Cleveland Clin, Cleveland, OH 44106 USA
[4] Univ Vermont, Dept Med, Divison Gastroenterol, Larner Coll Med, Burlington, VT USA
[5] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden
[6] Cleveland Clin, Dept Colorectal Surg, Cleveland, OH 44106 USA
[7] UNC Sch Med, Dept Med, Div Gastroenterol, Chapel Hill, NC USA
[8] Cleveland Clin, Dept Gastroenterol Hepatol & Nutr, Cleveland, OH 44106 USA
[9] NYU, Dept Surg, Grossman Sch Med, New York, NY 10016 USA
关键词
Crohn's disease; postoperative recurrence; resection; biologic therapy; MAGNETIC-RESONANCE ENTEROGRAPHY; COMPUTED-TOMOGRAPHY; ILEOCOLIC RESECTION; METAANALYSIS; ADALIMUMAB; RISK; PREVENTION; MANAGEMENT;
D O I
10.1093/ibd/izac158
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Lay Summary Postoperative recurrence of Crohn's disease is common after ileocecal resection. In this dual-center study, early initiation of an anti-TNF agent within 4 weeks following an ileocecal resection was associated with a reduction in postoperative recurrence of Crohn's disease. Background Postoperative recurrence (POR) of Crohn's disease (CD) is common after surgical resection. We aimed to compare biologic type and timing for preventing POR in adult CD patients after ileocecal resection (ICR). Methods We performed a retrospective cohort study of CD patients who underwent an ICR at 2 medical centers. Recurrence was defined by endoscopy (>= i2b Rutgeerts score) or radiography (active inflammation in neoterminal ileum) and stratified by type and timing of postoperative prophylactic biologic within 12 weeks following an ICR (none, tumor necrosis factor antagonists [anti-TNF], vedolizumab, and ustekinumab). Results We identified 1037 patients with CD who underwent an ICR. Of 278 (26%) who received postoperative prophylaxis, 80% were placed on an anti-TNF agent (n = 223) followed by ustekinumab (n = 28, 10%) and vedolizumab (n = 27, 10%). Prophylaxis was initiated in 35% within 4 weeks following an ICR and in 65% within 4 to 12 weeks. After adjusting for factors associated with POR, compared with no biologic prophylaxis, the initiation of an anti-TNF agent within 4 weeks following an ICR was associated with a reduction in POR (adjusted hazard ratio, 0.61; 95% CI, 0.40-0.93). Prophylaxis after 4 weeks following an ICR or with vedolizumab or ustekinumab was not associated with a reduction in POR compared with those who did not receive prophylaxis. Conclusion Early initiation of an anti-TNF agent within 4 weeks following an ICR was associated with a reduction in POR. Vedolizumab or ustekinumab, at any time following surgery, was not associated with a reduction in POR, although sample size was limited.
引用
收藏
页码:888 / 897
页数:10
相关论文
共 50 条
  • [31] Positive resection margins in Crohn's disease are a relevant risk factor for postoperative disease recurrence
    Kelm, Matthias
    Benatzky, Clara
    Buck, Viktoria
    Widder, Anna
    Schoettker, Katrin
    Rosenfeldt, Mathias
    Brand, Markus
    Schlegel, Nicolas
    Germer, Christoph-Thomas
    Meining, Alexander
    Nusrat, Asma
    Flemming, Sven
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [32] Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF,Vedolizumab or Ustekinumab: A Real-World Multicentre European Study
    Yanai, Henit
    Kagramanova, Anna
    Knyazev, Oleg
    Sabino, Joao
    Haenen, Shana
    Mantzaris, Gerassimos J.
    Mountaki, Katerina
    Armuzzi, Alessandro
    Pugliese, Daniela
    Furfaro, Federica
    Fiorino, Gionata
    Drobne, David
    Kurent, Tina
    Yassin, Sharif
    Maharshak, Nitsan
    Castiglione, Fabiana
    de Sire, Roberto
    Nardone, Olga Maria
    Farkas, Klaudia
    Molnar, Tamas
    Krznaric, Zeljko
    Brinar, Marko
    Chashkova, Elena
    Margolin, Moran Livne
    Kopylov, Uri
    Bezzio, Cristina
    Shitrit, Ariella Bar-Gil
    Lukas, Milan
    Chaparro, Maria
    Truyens, Marie
    Nancey, Stephane
    Lobaton, Triana
    Gisbert, Javier P.
    Saibeni, Simone
    Bacsur, Peter
    Bossuyt, Peter
    Schulberg, Julien
    Hoentjen, Frank
    Vigano, Chiara
    Palermo, Andrea
    Torres, Joana
    Reves, Joana
    Karmiris, Konstantinos
    Velegraki, Magdalini
    Savarino, Edoardo
    Markopoulos, Panagiotis
    Tsironi, Eftychia
    Ellul, Pierre
    Suarez, Cristina Calvino
    Weisshof, Roni
    JOURNAL OF CROHNS & COLITIS, 2022, 16 (12) : 1882 - 1892
  • [33] Influence of preoperative anti TNF alpha antibody therapy on postoperative recurrence of Crohn's disease
    Sekido, Yuki
    Ogino, Takayuki
    Takeda, Takashi
    Takeda, Mitsunobu
    Hata, Tsuyoshi
    Hamabe, Atsushi
    Takahashi, Hidekazu
    Miyoshi, Norikatsu
    Uemura, Mamoru
    Doki, Yuichiro
    Eguchi, Hidetoshi
    Mizushima, Tsunekazu
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [34] Plexitis as a predictive factor of early postoperative clinical recurrence in Crohn's disease
    Sokol, H.
    Polin, V.
    Lavergne-Slove, A.
    Panis, Y.
    Treton, X.
    Dray, X.
    Bouhnik, Y.
    Valleur, P.
    Marteau, P.
    GUT, 2009, 58 (09) : 1218 - 1225
  • [35] Early symptomatic recurrence after intestinal resection in Crohn's disease is unpredictable
    Kurer, M. A.
    Stamou, K. M.
    Wilson, T. R.
    Bradford, I. M. J.
    Leveson, S. H.
    COLORECTAL DISEASE, 2007, 9 (06) : 567 - 571
  • [36] Patterns and predictors of postoperative complications and recurrence after ileocecal resection for Crohn's disease: a national multicenter longitudinal study
    Soler-Silva, A.
    Sanchez-Guillen, L.
    Blanco-Antona, F.
    Barber, X.
    Millan, M.
    REIC Study Grp, J. M.
    TECHNIQUES IN COLOPROCTOLOGY, 2025, 29 (01)
  • [37] The Impact of Anti-Tumor Necrosis Factor Alpha Therapy on Postoperative Complications in Pediatric Crohn's Disease
    Dotlacil, Vojtech
    Bronsky, Jiri
    Hradsky, Ondrej
    Frybova, Barbora
    Coufal, Stepan
    Skaba, Richard
    Rygl, Michal
    EUROPEAN JOURNAL OF PEDIATRIC SURGERY, 2020, 30 (01) : 27 - 32
  • [38] The Influence of Microscopic Inflammation at Resection Margins on Early Postoperative Endoscopic Recurrence After Ileocaecal Resection for Crohn's Disease
    Poredska, Karolina
    Kunovsky, Lumir
    Marek, Filip
    Kala, Zdenek
    Prochazka, Vladimir
    Dolina, Jiri
    Zboril, Vladimir
    Kovalcikova, Petra
    Pavlik, Tomas
    Jabandziev, Petr
    Pavlovsky, Zdenek
    Vlazny, Jakub
    Mitas, Ladislav
    JOURNAL OF CROHNS & COLITIS, 2020, 14 (03) : 361 - 368
  • [39] Early Postoperative Anti-TNF Therapy Does Not Increase Complications Following Abdominal Surgery in Crohn's Disease
    Schad, Christine A.
    Haac, Bryce E.
    Cross, Raymond K.
    Syed, Ali
    Lonsako, Shumet
    Bafford, Andrea C.
    DIGESTIVE DISEASES AND SCIENCES, 2019, 64 (07) : 1959 - 1966
  • [40] The Association Between Drug Levels and Endoscopic Recurrence in Postoperative Patients with Crohn's Disease Treated with Tumor Necrosis Factor Inhibitors
    Fay, Shmuel
    Ungar, Bella
    Paul, Stephane
    Levartovsky, Asaf
    Yavzori, Miri
    Fudim, Ella
    Picard, Orit
    Eliakim, Rami
    Ben-Horin, Shomron
    Roblin, Xavier
    Kopylov, Uri
    INFLAMMATORY BOWEL DISEASES, 2017, 23 (11) : 1924 - 1929